FGFR2 and familial pancreatic carcinoma: We described four FGFR2 fusion-positive PDAC patients who exhibited excellent clinical outcomes with FGFR inhibitors and illustrated the landscape of FGFR fusions and SVs in a large cohort of pancreatic cancers.